SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 323 filers reported holding SAREPTA THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.96 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $3,640 | +37.7% | 30,027 | +30.1% | 0.09% | +59.3% |
Q2 2023 | $2,644 | +34.8% | 23,084 | +62.2% | 0.05% | +17.4% |
Q1 2023 | $1,962 | +79.5% | 14,236 | +68.7% | 0.05% | +48.4% |
Q4 2022 | $1,093 | -99.9% | 8,437 | -13.6% | 0.03% | -3.1% |
Q4 2020 | $1,665,000 | -15.5% | 9,768 | -30.4% | 0.03% | -39.6% |
Q3 2020 | $1,970,000 | -10.0% | 14,028 | +2.7% | 0.05% | -15.9% |
Q2 2020 | $2,189,000 | +70.1% | 13,655 | +3.8% | 0.06% | +26.0% |
Q1 2020 | $1,287,000 | +17.3% | 13,154 | +54.8% | 0.05% | +177.8% |
Q4 2019 | $1,097,000 | +81.9% | 8,500 | +6.2% | 0.02% | +50.0% |
Q3 2019 | $603,000 | -73.6% | 8,000 | -46.7% | 0.01% | -80.0% |
Q2 2019 | $2,280,000 | +139.0% | 15,000 | +87.5% | 0.06% | +150.0% |
Q1 2019 | $954,000 | -50.1% | 8,000 | -54.3% | 0.02% | -69.6% |
Q4 2018 | $1,910,000 | -70.4% | 17,500 | -56.2% | 0.08% | -53.8% |
Q3 2018 | $6,460,000 | -41.1% | 40,000 | -51.8% | 0.17% | -34.7% |
Q2 2018 | $10,971,000 | +129.6% | 83,000 | +28.7% | 0.26% | +73.5% |
Q1 2018 | $4,779,000 | -21.9% | 64,500 | -41.4% | 0.15% | -3.8% |
Q4 2017 | $6,120,000 | +11.5% | 110,000 | -9.1% | 0.16% | -23.0% |
Q3 2017 | $5,489,000 | +225.6% | 121,000 | +142.0% | 0.20% | +187.3% |
Q2 2017 | $1,686,000 | +26.6% | 50,000 | +11.1% | 0.07% | +34.0% |
Q1 2017 | $1,332,000 | +154.2% | 45,000 | +13.9% | 0.05% | +130.4% |
Q1 2015 | $524,000 | -67.1% | 39,500 | -64.1% | 0.02% | -57.4% |
Q4 2014 | $1,593,000 | +88.3% | 110,100 | +174.6% | 0.05% | +157.1% |
Q3 2014 | $846,000 | -1.4% | 40,100 | +39.2% | 0.02% | +16.7% |
Q2 2014 | $858,000 | -54.8% | 28,800 | -63.5% | 0.02% | -52.6% |
Q1 2014 | $1,897,000 | +106.9% | 78,950 | +75.4% | 0.04% | +90.0% |
Q4 2013 | $917,000 | -80.6% | 45,000 | -55.0% | 0.02% | -60.8% |
Q3 2013 | $4,724,000 | +210.4% | 100,000 | +150.0% | 0.05% | +15.9% |
Q2 2013 | $1,522,000 | – | 40,000 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ikarian Capital, LLC | 399,400 | $35,962,000 | 5.36% |
Avoro Capital Advisors LLC | 3,125,000 | $281,406,000 | 4.79% |
Varenne Capital Partners | 324,661 | $29,236,000 | 4.34% |
Evolutionary Tree Capital Management, LLC | 96,695 | $8,707,000 | 4.18% |
Ally Bridge Group (NY) LLC | 120,000 | $10,806,000 | 3.78% |
Casdin Capital, LLC | 1,350,000 | $121,568,000 | 3.43% |
Ghost Tree Capital, LLC | 100,000 | $9,005,000 | 3.23% |
GREAT POINT PARTNERS LLC | 145,405 | $13,094,000 | 2.91% |
Camber Capital Management LP | 825,000 | $74,291,000 | 2.55% |
Alpha DNA Investment Management LLC | 17,522 | $1,577,000 | 1.00% |